Giiant Pharma

We Make Small Molecules

About us

We are committed to build a robust IBD and GI-focused pipeline

Giiant Pharma inc. is a Montreal-based company founded by former Merck Frosst scientists. Combining experts in the field of gastroenterology and more than 25 years of experience in the field of industrial pharmaceutical research, Giiant Pharma aims at developing safer therapies for the treatment of inflammatory bowel diseases (IBD).

The expertise of our team leaders ranges from early drug discovery to late development and has translated to numerous market approvals.

our mission

Improving IBD drug tolerability

Drug tolerability, defined as the level of patient acceptance of adverse effects such as nausea, dry mouth, headache, diarrhea/constipation or mood change,  has a significant impact on quality of life and treatment adherence. Addressing tolerability issue in the early phase of drug discovery  is the cornerstone of Giiant’s research strategy. With the specific aim of bringing to patients a new therapeutic option for the treatment of IBD, Giiant Pharma has developed a gut-specific delivery platform. By targeting one single organ, improved tolerability arises from the lack of systemic exposure while sustained efficacy is ensured by the higher mucosal drug concentration at the site of inflammation.


The Management Team

Maxime Ranger, PhD, MBA

Chief executive officer

Bernard Côté, PhD

founder, Special Advisor

Véronique Bérubé, LL.B.

Head of operations & strategy

Patrick Colin, BPharm, PhD

Chief clinical officer

Elizabeth Kwong, PhD

Founder, Chief development officer

2021 Giiant Pharma All Rights Reserved